Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akeso
Pharma
Summit's global PD-1xVEGF data show new promising OS trend
With a fresh data cut in September, the death risk reduction by the ivonescimab regimen expanded to 22% with an improved nominal p value of 0.0332.
Angus Liu
Sep 7, 2025 3:30am
Ivonescimab, Fosun-Sitala, Hutchmed—Fierce Pharma Asia
Aug 29, 2025 8:15am
Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time
Aug 26, 2025 11:36am
Summit skips quarterly investor call as deal rumors swirl
Aug 12, 2025 10:29am
Fierce Biotech
China biotechs ‘reshaping’ US biopharma: Jefferies report
Jul 14, 2025 2:30pm
Summit in high-stakes deal talks with AstraZeneca: Bloomberg
Jul 7, 2025 10:45am
Fierce Biotech
Fierce Biotech
Fierce Biotech
Fierce Biotech
